Results 171 to 180 of about 768,287 (304)

Population Pharmacokinetics of Plasma‑Derived Factor X Using Clotting and Chromogenic Assays: A WAPPS‑Hemo Model

open access: yesHaemophilia, EarlyView.
ABSTRACT Background Hereditary factor X (FX) deficiency is a rare autosomal recessive bleeding disorder for which individualized pharmacokinetic (PK) assessment can support optimized prophylactic management. The WAPPS‐Hemo platform enables population pharmacokinetic (PopPK) individualized PK predictions based on sparse sampling.
Dagmar M. Hajducek   +4 more
wiley   +1 more source

Perioperative Management in Persons With Haemophilia on Rebalancing Therapies: A Narrative Review

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction Perioperative management in haemophilia often requires on‐demand use of clotting factor concentrates (CFC) and/or bypassing agents. Rebalancing agents (fitusiran, concizumab, marstacimab) offer a novel approach to prophylaxis by modulating endogenous anticoagulant pathways to restore haemostatic balance.
Amanda M. Henderson   +2 more
wiley   +1 more source

Surface cues shape procoagulant properties of amyloidogenic microclots. [PDF]

open access: yesCell Death Dis
Pretorius E   +4 more
europepmc   +1 more source

Shared Decision‐Making in Haemophilia Involves More Treatment Differentiators in 2026

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction Shared decision‐making regarding treatment choice in haemophilia care has become increasingly more complex and essential due to the availability of several innovative therapeutics that are characterized by their own advantages and limitations, which need to be tailored to individual patient needs.
Quentin Van Thillo   +2 more
wiley   +1 more source

Key Players and Pathways of Mast Cell Activation in Urticaria. [PDF]

open access: yesJ Inflamm Res
Jahn C   +4 more
europepmc   +1 more source

Coagulation Testing Practices and Guideline Adherence in Hemophilia A: A Retrospective Quality Assessment of a Dutch Expertise Hemophilia Treatment Center

open access: yesHaemophilia, EarlyView.
Abstract Background Coagulation testing in persons with hemophilia A (PwHA) is required for diagnosis, monitoring replacement therapy, assessment of adherence, and detection of inhibitors. However, data on testing practices are limited, and alignment with guideline recommendations is unclear.
A. P. Bavinck   +4 more
wiley   +1 more source

Trafficking thrombin receptors

open access: yesTrends in Cardiovascular Medicine, 1995
Lawrence F. Brass   +2 more
openaire   +1 more source

The Biological Basis of the Merlin CP‐GEP Assay: Integrin Signaling and Early Metastatic Competence in Cutaneous Melanoma

open access: yesInternational Journal of Dermatology, EarlyView.
Merlin CP‐GEP integrates mechanistic insights into a clinically actionable assay to predict SLN metastasis risk and inform personalized management of cutaneous melanoma. ABSTRACT The recent inclusion of the Merlin clinicopathologic–gene expression profile (CP‐GEP) assay in the National Comprehensive Cancer Network (NCCN) Melanoma Guidelines represents ...
Frank Z. Jing, Alexander Meves
wiley   +1 more source

Home - About - Disclaimer - Privacy